中国药房2025，Vol.36Issue(22)：2856-2861,6.DOI:10.6039/j.issn.1001-0408.2025.22.18
依柯胰岛素治疗2型糖尿病的快速卫生技术评估
Rapid health technology assessment of insulin icodec for the treatment of type 2 diabetes mellitus
摘要
Abstract
OBJECTIVE To comprehensively evaluate the efficacy,safety and cost-effectiveness of insulin icodec in treating type 2 diabetes mellitus(T2DM),providing evidence-based guidance for new drug selection in hospital and clinical medication decision-making.METHODS PubMed,Cochrane Library,Embase,CNKI,Wanfang,VIP and foreign health technology assessment(HTA)websites were searched by using rapid health technology assessment from inception to 15 July 2025 for systematic reviews/meta-analyses,pharmacoeconomic studies,and HTA reports on insulin icodec in the treatment of T2DM.After data extraction and quality assessment,the findings of the included studies were analyzed descriptively.RESULTS Ten systematic reviews/meta-analyses and three pharmacoeconomic studies were included.Among them,4 systematic reviews/meta-analyses were of high quality;the overall quality of the 3 pharmacoeconomic studies was relatively good.Regarding efficacy,insulin icodec was superior to once-daily basal insulin in reducing glycated hemoglobin(HbA1c)and in achieving the target of HbA1c＜7%(P＜0.05).No significant differences were observed between icodec insulin and comparators in lowering fasting plasma glucose(P＞0.05).For safety,insulin icodec did not increase the incidence of any adverse events(AEs),serious AEs,clinically significant hypoglycemia(random glucose＜3 mmol/L),injection-site reactions,or allergic reactions,compared with once-daily basal insulin overall(P＞0.05);however,insulin icodec was associated with a significant increase in body weight(P＜0.05).Domestic economic evaluations indicated that insulin icodec was more cost-effective than insulin glargine and insulin degludec when its annual costs were in the range of 784.90-1 145.96 and 597.66-736.34 US dollars,respectively.CONCLUSIONS Insulin icodec demonstrates favorable efficacy and safety profiles in the treatment of T2DM;however,attention should be paid to the risk of weight gain.Under China's healthcare system,insulin icodec demonstrates greater economic value only when the patient's weekly required basal insulin dose falls within a specific range,and clinical practice requires individualization.关键词
依柯胰岛素/2型糖尿病/疗效/安全性/经济性/快速卫生技术评估Key words
insulin icodec/type 2 diabetes mellitus/efficacy/safety/cost-effectiveness/rapid health technology assessment分类
药学引用本文复制引用
李杰,李宏,陈冠吉,常晓艳,杨祥,蒋志涛..依柯胰岛素治疗2型糖尿病的快速卫生技术评估[J].中国药房,2025,36(22):2856-2861,6.基金项目
江苏省卫生健康委医学科研项目(No.苏卫科教[2022]14号) （No.苏卫科教[2022]14号）
